ArticleThe oncologist2016

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Iordanis Gravanis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.